Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434431 | 1.00 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL9485864 | 1.00 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL30698079 | 0.98 | CTSC (0.56) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL30051660 | 0.97 | CTSD (0.55) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL30052830 | 0.94 | OPRD1 (0.53) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL29377179 | 0.93 | MME (0.57) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL30052163 | 0.93 | CTSD (0.54) | CTSCALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL4389285 | 0.93 | CTSC (0.51) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL16144769 | 0.91 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL31721066 | 0.91 | OPRM1 (0.53) | CTSCALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087804-A1 | METHOD FOR PRODUCING SELF-ASSEMBLING DIPEPTIDES | FERTINAGRO BIOTECH, S.L. (ES) | 2026-04-30 | — | — | WO | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240279298-A1 | GLUCAGON ANALOG AND MEDICAL USE THEREOF | BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD. (CN) | 2024-08-22 | — | — | US | claimed |
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | claimed |
| US-11814417-B2 | GIP agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2023-11-14 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-116589528-A | Lumbricus guangdong characteristic peptide and application thereof | 江阴天江药业有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-116411039-A | Preparation method, purification method and application of active peptide for inhibiting alpha-glucosidase | 桂林三金药业股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2023120844-A1 | COMPOSITION FOR MASS PROLIFERATING NATURAL KILLER CELLS, COMPRISING NOVEL PEPTIDE, AND METHOD FOR MASS PROLIFERATING NATURAL KILLER CELLS BY USING SAME | 엔케이젠 주식회사 | 2023-06-29 | — | — | WO | claimed |
| EP-3952991-A1 | RUSALATIDE ACETATE COMPOSITIONS | Affirmed Pharma, LLC (US) | 2022-02-16 | — | — | EP | claimed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | claimed |
| US-5206221-A | Removal of cytotoxic lymphocytes | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-04-27 | — | — | US | claimed |
| EP-0500745-A1 | METAL-PEPTIDE COMPOSITIONS AND COSMETIC METHODS FOR STIMULATING HAIR GROWTH | PROCYTE CORPORATION (US) | 1992-09-02 | — | — | EP | claimed |
| EP-0489860-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS. | PROCYTE CORP (US) | 1992-06-17 | — | — | EP | claimed |
| US-5068223-A | Dipeptides and derivatives used to deplete cytotoxic lymphocytes | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 1991-11-26 | — | — | US | claimed |
| US-5047401-A | Bone marrow transplants | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-09-10 | — | — | US | claimed |
| WO-1991007431-A1 | METAL-PEPTIDE COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH | PROCYTE CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1991003488-A1 | METHODS AND COMPOSITIONS FOR HEALING ULCERS | PROCYTE CORPORATION (US) | 1991-03-21 | — | — | WO | claimed |
| US-4752602-A | DEACTIVATION CYTOTOXIC LYMPHOCYTES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1988-06-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | CTSC 97/4885ALPI 413/4885PKM 1976/4885 |
| US-11814417-B2 | GIP agonist compounds and methods | GIPR, GLP1R, GPR119 | CTSC 97/4885ALPI 413/4885PKM 1976/4885 |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | CTSC 97/4885ALPI 413/4885PKM 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.